Pharmacologic treatments for covid-19 patients
Recombinant human granulocyte colony-stimulating factor vs Standard care
This comparison will not be updated. Last search date 14 Dec, 2022
Hospitalized patients
Forest plots
(last update: 2021-06-10)
To access all information :
- click here for Hospitalized patients
You can print it as a pdf. You can also click on each forest plot with your right mouse button and download.
Permanent URL for this comparison: https://covid-nma.com/living_data/index.php?comparison=87
Back to your research
| Trial | Funding | Comparisons | Design | Participants | Sample size | Overall risk of bias Highest assessment |
Full description | |
|---|---|---|---|---|---|---|---|---|
| Treatment 1 | Treatment 2 | |||||||
| ChiCTR2000030007 Cheng L, JAMA Intern Med, 2020 Full text Commentary |
Mixed |
recombinant human granulocyte colony-stimulating factor |
Standard care |
RCT | Patients with confirmed COVID-19 (moderate-severe) admitted to 3 centers in China | N=200 |
Some concerns Details |
|